Your browser doesn't support javascript.
loading
Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.
Bulanova, Daria; Ianevski, Aleksandr; Bugai, Andrii; Akimov, Yevhen; Kuivanen, Suvi; Paavilainen, Henrik; Kakkola, Laura; Nandania, Jatin; Turunen, Laura; Ohman, Tiina; Ala-Hongisto, Hanna; Pesonen, Hanna M; Kuisma, Marika S; Honkimaa, Anni; Walton, Emma L; Oksenych, Valentyn; Lorey, Martina B; Guschin, Dmitry; Shim, Jungmin; Kim, Jinhee; Than, Thoa T; Chang, So Young; Hukkanen, Veijo; Kulesskiy, Evgeny; Marjomaki, Varpu S; Julkunen, Ilkka; Nyman, Tuula A; Matikainen, Sampsa; Saarela, Jani S; Sane, Famara; Hober, Didier; Gabriel, Gülsah; De Brabander, Jef K; Martikainen, Miika; Windisch, Marc P; Min, Ji-Young; Bruzzone, Roberto; Aittokallio, Tero; Vähä-Koskela, Markus; Vapalahti, Olli; Pulk, Arto; Velagapudi, Vidya; Kainov, Denis E.
Afiliação
  • Bulanova D; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. daria.bulanova@helsinki.fi.
  • Ianevski A; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. aleksandr.ianevski@helsinki.fi.
  • Bugai A; Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki 00290, Finland. andrii.bugai@helsinki.fi.
  • Akimov Y; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. yevhen.akimov@helsinki.fi.
  • Kuivanen S; Department of Virology, University of Helsinki, Helsinki 00290, Finland. suvi.kuivanen@helsinki.fi.
  • Paavilainen H; Department of Virology, University of Turku, Turku 20520, Finland. hojpaa@utu.fi.
  • Kakkola L; Department of Virology, University of Turku, Turku 20520, Finland. laura.kakkola@utu.fi.
  • Nandania J; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. jatin.nandania@helsinki.fi.
  • Turunen L; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. laura.turunen@helsinki.fi.
  • Ohman T; Institute of Biotechnology, University of Helsinki, Helsinki 00014, Finland. tiina.ohman@helsinki.fi.
  • Ala-Hongisto H; Biomedicum Functional Genomics Unit (FuGU), Helsinki, Helsinki 00290, Finland. hanna.ala-hongisto@helsinki.fi.
  • Pesonen HM; Biomedicum Functional Genomics Unit (FuGU), Helsinki, Helsinki 00290, Finland. hanna.m.pesonen@helsinki.fi.
  • Kuisma MS; Biomedicum Functional Genomics Unit (FuGU), Helsinki, Helsinki 00290, Finland. marika.kuisma@helsinki.fi.
  • Honkimaa A; Department of Virology, University of Tampere, Tampere 33520, Finland. Anni.Honkimaa@uta.fi.
  • Walton EL; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7028, Norway. emma.l.walton@ntnu.no.
  • Oksenych V; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7028, Norway. valentyn.oksenych@ntnu.no.
  • Lorey MB; University of Helsinki and Helsinki University Hospital, Rheumatology, Helsinki 00290, Finland. martina.lorey@helsinki.fi.
  • Guschin D; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. albanec2@gmail.com.
  • Shim J; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. jungmin.shim@ip-korea.org.
  • Kim J; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. jinhee.kim@ip-korea.org.
  • Than TT; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. thoa.than@ip-korea.org.
  • Chang SY; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. soyoung.chang@ip-korea.org.
  • Hukkanen V; Department of Virology, University of Turku, Turku 20520, Finland. veijo.hukkanen@utu.fi.
  • Kulesskiy E; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. evgeny.kulesskiy@helsinki.fi.
  • Marjomaki VS; Department of Biological and Environmental Science/Nanoscience center, University of Jyväskylä, Jyväskylä 40500, Finland. varpu.s.marjomaki@jyu.fi.
  • Julkunen I; Department of Virology, University of Turku, Turku 20520, Finland. ilkka.julkunen@utu.fi.
  • Nyman TA; Institute of Biotechnology, University of Helsinki, Helsinki 00014, Finland. t.a.nyman@medisin.uio.no.
  • Matikainen S; Department of Immunology, University of Oslo, Oslo 0424, Norway. t.a.nyman@medisin.uio.no.
  • Saarela JS; University of Helsinki and Helsinki University Hospital, Rheumatology, Helsinki 00290, Finland. sampsa.matikainen@helsinki.fi.
  • Sane F; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. jani.saarela@helsinki.fi.
  • Hober D; University of Lille, CHU Lille laboratoire de Virologie, EA3610, F-59037 Lille, France. famara.sane@chru-lille.fr.
  • Gabriel G; University of Lille, CHU Lille laboratoire de Virologie, EA3610, F-59037 Lille, France. didier.hober@chru-lille.fr.
  • De Brabander JK; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg 20251, Germany. guelsah.gabriel@hpi.uni-hamburg.de.
  • Martikainen M; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9038, USA. jef.debrabander@utsouthwestern.edu.
  • Windisch MP; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala 75237, Sweden. miika.martikainen@igp.uu.se.
  • Min JY; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. marc.windisch@ip-korea.org.
  • Bruzzone R; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. jiyoung.min@ip-korea.org.
  • Aittokallio T; Institut Pasteur Korea, Gyeonggi-do 13488, Korea. bruzzone@hkucc.hku.hk.
  • Vähä-Koskela M; HKU-Pasteur Research Pole, School of Public Health, University of Hong Kong, Hong Kong, China. bruzzone@hkucc.hku.hk.
  • Vapalahti O; Department of Cell Biology and Infection, Institut Pasteur, Paris 75015, France. bruzzone@hkucc.hku.hk.
  • Pulk A; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. tero.aittokallio@helsinki.fi.
  • Velagapudi V; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki 00290, Finland. markus.vaha-koskela@helsinki.fi.
  • Kainov DE; Department of Virology and Immunology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland. olli.vapalahti@helsinki.fi.
Viruses ; 9(10)2017 09 25.
Article em En | MEDLINE | ID: mdl-28946654
ABSTRACT
Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Replicação Viral / Vírus / Apoptose / Proteínas Proto-Oncogênicas c-bcl-2 / Benzotiazóis / Isoquinolinas Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Finlândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Replicação Viral / Vírus / Apoptose / Proteínas Proto-Oncogênicas c-bcl-2 / Benzotiazóis / Isoquinolinas Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Finlândia